The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC


Ramucirumab monotherapy has received an approval from the FDA for the treatment of patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/mL and have been previously treated with sorafenib.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.